

# Stabilis



Avelumab



Tradename

Bavencio

Belgium, France, Germany, Great Britain, Spain, Switzerland



## Stability in solutions

		3.2 mg/mL	20-25°C		24			4474
		3.2 mg/mL	20-25°C		24			4474
		3.2 mg/mL	20-25°C		24			4474
		3.2 mg/mL	20-25°C		24			4474
		3.2 mg/mL	20-25°C		24			4474
		3.2 mg/mL	20-25°C		24			4474
		3.2 mg/mL	20-25°C		24			4474
		3.2 mg/mL	20-25°C		24			4474
		3.2 mg/mL	20-25°C		24			4474
		3.2 mg/mL	20-25°C		24			4474



























## References

	Type	Publication
4474	Manufacturer	Avelumab, Bavencio® - Summary of Product Characteristics Updated 01-Nov-2019 Merck - Pfizer 2019



# Dictionary

 Anticancer drug	 Injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Length of time
 Biosimilar	 Conflicting data
 References	 Glass
 Sodium chloride 0,9%	 Protect from light
 Hour	 Sodium chloride 0,45%
 Polyvinyl chloride	 Polypropylene
 Polyethylene	 Ethylene vinyl acetate
 References	 Dictionary